Compare Acadia Healthcare Company Inc (ACHC) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance

ACHC trades at $31.85, up 0.22% today, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 EPS of $0.38, beating estimates, but maintains negative net income margins near -33%. Revenue is stable at $3.3B, while analyst consensus is a Buy with a $36 price target. Recent news highlights ongoing litigation and operational progress.

Outlook is mixed: strong analyst support and earnings beats suggest upside, but profitability challenges and legal investigations pose significant risks. The stock's valuation appears reasonable with a P/E of 19.82, yet negative ROE and net income require careful monitoring for turnaround execution.

Marsh & McLennan (MRSH) trades at $189.13, down 0.87% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats in Q2 2026, with EPS of $2.96 versus $2.88 expected, and 6% revenue growth highlight operational strength. The company announced the acquisition of Accel to expand its Midwest insurance reach, signaling strategic growth. Valuation metrics show a P/E of 23.35 and robust profitability with a net income margin of 14.24%.

The outlook remains positive with a consensus price target of $202.89, offering potential upside. Risks include margin pressure from rising expenses and soft P&C pricing. Institutional activity is mixed, with Bank of America reducing its stake while others like Bank of Nova Scotia increased holdings. The stock presents a solid long-term growth opportunity amid cyclical insurance sector headwinds.